AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24131370 — intervention group
Group type: COMPARATOR
Intervention: Standard dual handrim Action 3 wheelchair
Number of subjects: 4
Study 23453448 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 46
Study 23453448 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 46
Study 20842172 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 1: self-selection of snacks
Number of subjects: 10
Study 20842172 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 2: preload (300 kcal: 40% protein, 40% carbohydrates, 20% fat) at 15 min before meals
Number of subjects: 10
Study 20842172 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 3: preload (300 kcal: 40% protein, 40% carbohydrates, 20% fat) at ∼ 50 min before meals
Number of subjects: 10
Study 18347974 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Nostril Yoga Breathing (RNYB)
Number of subjects: 21
Study 18347974 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Nostril Yoga Breathing (ANYB)
Number of subjects: 21
Study 18347974 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Nostril Yoga Breathing (LNYB)
Number of subjects: 21
Study 18347974 — intervention group
Group type: COMPARATOR
Intervention: Breath Awareness (BAW)
Number of subjects: 21
Study 18347974 — intervention group
Group type: COMPARATOR
Intervention: Normal Breathing (CTL)
Number of subjects: 21
Study 16418802 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with observed viral load blips
Number of subjects: 16
Study 16418802 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) without observed viral load blips
Number of subjects: 16
Study 12918866 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching for 30 seconds (n = 26)
Number of subjects: 101
Study 12918866 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching for 1 minute (n = 24)
Number of subjects: 101
Study 12918866 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching for 2 minutes (n = 27)
Number of subjects: 101
Study 12918866 — intervention group
Group type: COMPARATOR
Intervention: No stretch control group (n = 24)
Number of subjects: 101
Study 10856094 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m² (D100)
Number of subjects: 373
Study 10856094 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² (D75)
Number of subjects: 373
Study 10856094 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine or Ifosfamide (V/I)
Number of subjects: 373
Study 9052337 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA (0.8 mg/kg, up to a maximum dose of 80 mg)
Number of subjects: 1425
Study 9052337 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (coronary arteriography with percutaneous angioplasty, if feasible)
Number of subjects: 1425
Study 9052337 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients > 75 years of age
Number of subjects: 1425
Study 9052337 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher heparin levels
Number of subjects: 1425
Study 9052337 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher peak D‐dimer levels
Number of subjects: 1425
Study 9052337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower nadir fibrinogen levels
Number of subjects: 1425
Study 9052337 — intervention group
Group type: COMPARATOR
Intervention: t‐PA
Number of subjects: 1425
Study 8466349 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (Duraflo II)
Number of subjects: 30
Study 8466349 — intervention group
Group type: COMPARATOR
Intervention: Control (noncoated circuit)
Number of subjects: 30
Study 30040767 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal M1-tDCS
Number of subjects: 32
Study 30040767 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 32
Study 28557558 — intervention group
Group type: EXPERIMENTAL
Intervention: Grow2Gether intervention (Facebook peer-group)
Number of subjects: 87
Study 28557558 — intervention group
Group type: COMPARATOR
Intervention: Text message appointment reminders (Control)
Number of subjects: 87
Study 26051095 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg for 12 weeks
Number of subjects: 0
Study 26051095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23288496 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal school-based depression prevention programme
Number of subjects: 834
Study 23288496 — intervention group
Group type: COMPARATOR
Intervention: Control programmes
Number of subjects: 834
Study 20601692 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant HIV infection
Number of subjects: 848
Study 20601692 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma viral load >100,000 copies ml⁻¹
Number of subjects: 848
Study 20601692 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age < 20 years
Number of subjects: 848
Study 18190710 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic containing 4 strains of live bacteria taken daily for 3 months
Number of subjects: 147
Study 18190710 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo taken daily for 3 months
Number of subjects: 147
Study 17174182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy
Number of subjects: 205
Study 17174182 — intervention group
Group type: COMPARATOR
Intervention: Coronary revascularization
Number of subjects: 205
Study 12711121 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1000 mg/m(2), days 1, 8 and 15, every 4 weeks
Number of subjects: 169
Study 12711121 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (100 mg/m(2), day 1) plus Vindesine (3 mg/m(2), days 1 and 15) (PV)
Number of subjects: 169
Study 10921160 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhu Yu Hua Tan Tang plus general treatment
Number of subjects: 44
Study 10921160 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhu Yu Hua Tan Tang
Number of subjects: 44
Study 10921160 — intervention group
Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 44
Study 8832309 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 132
Study 8832309 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 132
Study 1570392 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol (80 mg over 3 days)
Number of subjects: 10
Study 1570392 — intervention group
Group type: COMPARATOR
Intervention: buspirone (30 mg orally)
Number of subjects: 10
Study 3891779 — intervention group
Group type: EXPERIMENTAL
Intervention: Directigen tested within 4 hours of sampling
Number of subjects: 964
Study 3891779 — intervention group
Group type: COMPARATOR
Intervention: Directigen tested after overnight storage
Number of subjects: 964
Study 30044439 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanines (60 mg/day)
Number of subjects: 72
Study 30044439 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthophylls (6 mg L + 2 mg Z/day)
Number of subjects: 72
Study 30044439 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanines (60 mg/day) + Xanthophylls (6 mg L + 2 mg Z/day)
Number of subjects: 72
Study 30044439 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 72
Study 27454919 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid-free regimen with Tac and MMF starting at 3 g/d, dose adjusted from day 5
Number of subjects: 187
Study 27454919 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid regimen with Tac and fixed-dose MMF (2 g/d)
Number of subjects: 187
Study 27454919 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid-free regimen with Tac and MMF
Number of subjects: 187
Study 24903207 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational football (F; n = 9)
Number of subjects: 26
Study 24903207 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (R; n = 9)
Number of subjects: 26
Study 24903207 — intervention group
Group type: COMPARATOR
Intervention: Inactive controls (C; n = 8)
Number of subjects: 26
Study 22420890 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma FABP4 levels
Number of subjects: 578
Study 22420890 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of FABP4 in women
Number of subjects: 578
Study 20357372 — intervention group
Group type: EXPERIMENTAL
Intervention: GLAR + MET + EXE
Number of subjects: 48
Study 20357372 — intervention group
Group type: EXPERIMENTAL
Intervention: GLAR + MET + SITA
Number of subjects: 48
Study 20357372 — intervention group
Group type: COMPARATOR
Intervention: GLAR + MET
Number of subjects: 48
Study 16956036 — intervention group
Group type: EXPERIMENTAL
Intervention: ST analysis of fetal ECG (group A)
Number of subjects: 134
Study 16956036 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring methods (group B)
Number of subjects: 134
Study 14871281 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin-containing red pepper sauce
Number of subjects: 10
Study 14871281 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 11752915 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg)
Number of subjects: 80
Study 11752915 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol (0.5‐1.0 microg/kg/min)
Number of subjects: 80
Study 11752915 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 80
Study 11752915 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 80
Study 9246136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg/day orally for seven days)
Number of subjects: 54
Study 9246136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 9246136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 54
Study 8502357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sygen‐‐monosialoganglioside 40 mg daily
Number of subjects: 65
Study 8502357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Vitamin PP)
Number of subjects: 65
Study 3329968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (500 mg orally, twice daily)
Number of subjects: 44
Study 3329968 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg orally, once daily)
Number of subjects: 44
Study 3329968 — intervention group
Group type: COMPARATOR
Intervention: Diflunisal
Number of subjects: 44
Study 3329968 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 44
Study 31278194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet)
Number of subjects: 203
Study 31278194 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study 28039097 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic vision
Number of subjects: 20
Study 28039097 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopic vision
Number of subjects: 20
Study 24978872 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day (up to 100 mg/day)
Number of subjects: 102
Study 24978872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 24239019 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttonhole needling
Number of subjects: 140
Study 24239019 — intervention group
Group type: COMPARATOR
Intervention: Standard needling
Number of subjects: 140
Study 22244561 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant tricuspid annuloplasty (Cosgrove‐Edwards annuloplasty ring)
Number of subjects: 44
Study 22244561 — intervention group
Group type: COMPARATOR
Intervention: No concomitant tricuspid annuloplasty (Control)
Number of subjects: 44
Study 20033601 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided neurosurgery
Number of subjects: 12
Study 17515857 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT) agent at 1,500 U/24 h (combined group) for 3 days
Number of subjects: 24
Study 17515857 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT) agent at 500 U/8 h (divided group) for 3 days
Number of subjects: 24
Study 16264051 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus fumigatus inhalation
Number of subjects: 28
Study 16264051 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 28
Study 11850098 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose, 100 mg thrice daily
Number of subjects: 27
Study 11850098 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide, 1 mg thrice daily
Number of subjects: 27
Study 10201424 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual simple reaction time (SRT) task
Number of subjects: 23
Study 10201424 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncued four choice reaction time (CRT) task
Number of subjects: 23
Study 10201424 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully cued four choice reaction time (CRT) task
Number of subjects: 23
Study 10201424 — intervention group
Group type: EXPERIMENTAL
Intervention: S1-S2 interval effects on CRTs
Number of subjects: 23
Study 10201424 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ms S1-S2 interval
Number of subjects: 23
Study 10201424 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 ms S1-S2 interval
Number of subjects: 23
Study 10201424 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 ms and 3200 ms S1-S2 intervals
Number of subjects: 23
Study 7572739 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula (pre)
Number of subjects: 68
Study 7572739 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula with ribonucleotides (pre+RN)
Number of subjects: 68
Study 7572739 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed babies (reference group)
Number of subjects: 68
Study 2157581 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 20
Study 2157581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 109592 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 or 50 microgram doses of meningococcal group A polysaccharide vaccine
Number of subjects: 108
Study 109592 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microgram dose of meningococcal group A polysaccharide vaccine
Number of subjects: 108
Study 109592 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microgram dose of meningococcal group A polysaccharide vaccine
Number of subjects: 108
Study 31491340 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR markers identified from transcriptome assembly
Number of subjects: 88
Study 31491340 — intervention group
Group type: EXPERIMENTAL
Intervention: cDNA library sequencing using Illumina NovaSeq. 6000
Number of subjects: 88
Study 31491340 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical clustering of accessions
Number of subjects: 88
Study 27343344 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS treatment
Number of subjects: 30
Study 27343344 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 25518053 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 255
Study 23897241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube cleaning three times a day (group A)
Number of subjects: 45
Study 23897241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube cleaning twice daily (group B)
Number of subjects: 45
Study 23897241 — intervention group
Group type: COMPARATOR
Intervention: No endotracheal tube cleaning (group C)
Number of subjects: 45
Study 21827704 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex sublingual immunotherapy
Number of subjects: 28
Study 21827704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 19841762 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser ablation on dentin
Number of subjects: 20
Study 19841762 — intervention group
Group type: COMPARATOR
Intervention: Control group (ground using #600 SiC paper)
Number of subjects: 20
Study 16759925 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI zygotes
Number of subjects: 250
Study 16759925 — intervention group
Group type: COMPARATOR
Intervention: IVF zygotes
Number of subjects: 250
Study 16759925 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI zygotes from severe oligozoospermia
Number of subjects: 250
Study 16759925 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI zygotes from azoospermia
Number of subjects: 250
Study 16759925 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI zygotes from oligozoospermia
Number of subjects: 250
Study 15563438 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium dairy drink
Number of subjects: 154
Study 15563438 — intervention group
Group type: COMPARATOR
Intervention: Control drink reconstituted with water
Number of subjects: 154
Study 12516677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare Elite toothbrush
Number of subjects: 45
Study 12516677 — intervention group
Group type: COMPARATOR
Intervention: Sonicare Advance toothbrush
Number of subjects: 45
Study 9582586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (100 mg)
Number of subjects: 7
Study 9582586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg)
Number of subjects: 7
Study 8291826 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening with mammography and physical examination
Number of subjects: 2
Study 8291826 — intervention group
Group type: COMPARATOR
Intervention: Annual screening with mammography
Number of subjects: 2
Study 2491404 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid
Number of subjects: 32
Study 2491404 — intervention group
Group type: COMPARATOR
Intervention: indomethacin
Number of subjects: 32
Study 1000146 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuously reinforced group
Number of subjects: 8
Study 1000146 — intervention group
Group type: EXPERIMENTAL
Intervention: Variably reinforced group
Number of subjects: 8
Study 1000146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 8
Study 31882527 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN) for 7 days
Number of subjects: 4011
Study 31882527 — intervention group
Group type: COMPARATOR
Intervention: No GTN
Number of subjects: 4011
Study 28181363 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 51
Study 28181363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 25906949 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron supplementation (10 mg/day)
Number of subjects: 113
Study 25906949 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 113
Study 22771782 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 12
Study 20335550 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 capsule/day of omega-3 PUFA supplement providing 0.84 g DHA + EPA
Number of subjects: 48
Study 20335550 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 capsules/day of omega-3 PUFA supplement providing 2.52 g DHA + EPA
Number of subjects: 48
Study 20335550 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 capsules/day of omega-3 PUFA supplement providing 5.04 g DHA + EPA
Number of subjects: 48
Study 20335550 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 capsules/day of omega-3 PUFA supplement providing 7.56 g DHA + EPA
Number of subjects: 48
Study 18313671 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgical incision
Number of subjects: 50
Study 18313671 — intervention group
Group type: COMPARATOR
Intervention: Bougie dilation
Number of subjects: 50
Study 16131771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 115
Study 16131771 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (without prior i.v. access)
Number of subjects: 115
Study 16131771 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (with prior i.v. access)
Number of subjects: 115
Study 16131771 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam
Number of subjects: 115
Study 12149842 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Number of subjects: 113
Study 10503678 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment for pupils with s-ferritin <15 microg/l, duration of 3 months
Number of subjects: 176
Study 10503678 — intervention group
Group type: COMPARATOR
Intervention: Screening for anaemia and iron deficiency
Number of subjects: 176
Study 8607723 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug treatment (chlorthalidone 15 mg/d, acebutolol hydrochloride 400 mg/d, doxazosin mesylate 2 mg/d, amlodipine besylate 5 mg/d, enalapril maleate 5 mg/d)
Number of subjects: 902
Study 8607723 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug treatment (all active drugs combined)
Number of subjects: 902
Study 8607723 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 902
Study 8607723 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug treatment
Number of subjects: 902
Study 8607723 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention only
Number of subjects: 902
Study 1953524 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b (3 million units subcutaneously thrice weekly for 24 weeks)
Number of subjects: 40
Study 1953524 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b
Number of subjects: 40
Study 1953524 — intervention group
Group type: COMPARATOR
Intervention: Control group (observed without treatment for 12 months)
Number of subjects: 40
Study 7050035 — intervention group
Group type: EXPERIMENTAL
Intervention: misonidazole (2.0 gm per m2 body surface) with radiation
Number of subjects: 97
Study 7050035 — intervention group
Group type: COMPARATOR
Intervention: radiation (3600 rad in 17 days) without misonidazole
Number of subjects: 97
Study 31430524 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodating child's healthy preferences
Number of subjects: 0
Study 31430524 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodating child's indulgent preferences
Number of subjects: 0
Study 31430524 — intervention group
Group type: EXPERIMENTAL
Intervention: Imposing own preferences
Number of subjects: 0
Study 28398968 — intervention group
Group type: EXPERIMENTAL
Intervention: AtDCS+treadmill
Number of subjects: 18